These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8717785)

  • 1. [Oral antidiabetics: acarbose].
    Taurand S
    Soins; 1996 May; (606):61-2. PubMed ID: 8717785
    [No Abstract]   [Full Text] [Related]  

  • 2. Differential response of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose.
    Hegele RA; Connelly PW; Palmason C; Jenkins DJ; Wolever TM
    Diabetes Care; 1995 Feb; 18(2):272-3. PubMed ID: 7729310
    [No Abstract]   [Full Text] [Related]  

  • 3. Acarbose: in search for its real indications in current medical practice.
    Lerman I; Gómez Perez FJ; Aguilar-Salinas CA; Rodrigo JA
    Diabetes Care; 1996 Jan; 19(1):94-5. PubMed ID: 8720547
    [No Abstract]   [Full Text] [Related]  

  • 4. [The use of acarbose for treating diabetic patients].
    Balabolkin MI; Dedov II; Mkrtumian AM; Ametov AS; Kakhnovskiĭ IM; Chazova TE; Koroleva TS; Kochergina II; Matveeva LS
    Ter Arkh; 1994; 66(10):20-1. PubMed ID: 7863437
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus.
    Rodier M; Richard JL; Monnier L; Mirouze J
    Diabete Metab; 1988; 14(1):12-4. PubMed ID: 3292303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of acarbose treatment of NIDDM].
    Wainstein J; Jedwab M
    Harefuah; 1997 Feb; 132(4):258-63, 311. PubMed ID: 9153894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple oral antidiabetic therapy.
    Kaye TB
    J Diabetes Complications; 1998; 12(6):311-3. PubMed ID: 9877464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose for diabetes mellitus.
    Med Lett Drugs Ther; 1996 Feb; 38(967):9-10. PubMed ID: 8559114
    [No Abstract]   [Full Text] [Related]  

  • 9. An interaction between digoxin and acarbose.
    Ben-Ami H; Krivoy N; Nagachandran P; Roguin A; Edoute Y
    Diabetes Care; 1999 May; 22(5):860-1. PubMed ID: 10332701
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of acarbose in the treatment of diabetes mellitus].
    Scheen AJ
    Diabetes Metab; 1998 Sep; 24(4):385-90. PubMed ID: 9805654
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
    Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
    Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acarbose in the treatment of type 2 diabetes].
    Amoretti R; Cicconetti C; De Nichilo M; Teodonio C; Fasani R; Carosi M
    Minerva Dietol Gastroenterol; 1986; 32(1):53-9. PubMed ID: 3517699
    [No Abstract]   [Full Text] [Related]  

  • 14. Aminotransferase activity and acarbose treatment in patients with type 2 diabetes.
    Gentile S; Turco S; Guarino G; Sasso FC; Torella R
    Diabetes Care; 1999 Jul; 22(7):1217-8. PubMed ID: 10388994
    [No Abstract]   [Full Text] [Related]  

  • 15. No relationship between carbohydrate intake and effect of acarbose on HbA1c or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate.
    Wolever TM; Chiasson JL; Josse RG; Hunt JA; Palmason C; Rodger NW; Ross SA; Ryan EA; Tan MH
    Diabetes Care; 1998 Oct; 21(10):1612-8. PubMed ID: 9773719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glucobay in the therapy of patients with non-insulin-dependent diabetes mellitus].
    Bodnar PM; Kononenko LO
    Lik Sprava; 1998 May; (3):111-4. PubMed ID: 9695585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.
    Coniff RF; Shapiro JA; Seaton TB
    Arch Intern Med; 1994 Nov; 154(21):2442-8. PubMed ID: 7979840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure: a randomised-multicentric trial in primary health-care. Diabetes and Acarbose Research Group.
    Costa B; Piñol C
    Diabetes Res Clin Pract; 1997 Oct; 38(1):33-40. PubMed ID: 9347244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study.
    Spengler M; Cagatay M
    Clin Invest Med; 1995 Aug; 18(4):325-31. PubMed ID: 8549020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acarbose: can it take a bite out of type 2 diabetes mellitus?
    Ponte CD
    Ann Pharmacother; 1996 Nov; 30(11):1333-5. PubMed ID: 8913419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.